Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIVATE trial of tropifexor and licogliflozin in adults with NASH and liver fibrosis
MOH_2021-10-21_010338Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tropifexor and licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Novartis. Primary endpoints: Fibrosis improvement without worsening of NASH at week 48 and NASH resolution without worsening of fibrosis at week 48. Started Jul 2021; status: completed.
02
Drugs
tropifexorlicogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2021-10-21_010338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-21_010338.